{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T01:27:18Z","timestamp":1755221238090,"version":"3.43.0"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:sec>\n            <jats:title>Objectives<\/jats:title>\n            <jats:p>Chemotherapy-induced hematological toxicities are potentially life-threatening adverse drug reactions that vary between individuals. Recently, <jats:italic toggle=\"yes\">JMJD1C<\/jats:italic> has been associated with gemcitabine\/carboplatin-induced thrombocytopenia in non-small-cell lung cancer patients, making it a candidate marker for predicting the risk of toxicity. This study investigates if <jats:italic toggle=\"yes\">JMJD1C<\/jats:italic> knockdown affects gemcitabine\/carboplatin-sensitivity in cell lines.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Lentiviral transduction-mediated shRNA knockdown of <jats:italic toggle=\"yes\">JMJD1C<\/jats:italic> in the cell lines K562 and MEG-01 were performed using shRNA#32 and shRNA#33. The knockdown was evaluated using qPCR. Cell proliferation, viability, and gemcitabine\/carboplatin-sensitivity were subsequently determined using cell counts, trypan blue, and the MTT assay.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>ShRNA#33 resulted in <jats:italic toggle=\"yes\">JMJD1C<\/jats:italic> downregulation by 56.24% in K562 and 68.10% in MEG-01. Despite incomplete knockdown, proliferation (reduction of cell numbers by 61\u201368%, day 7 post-transduction) and viability (reduction by 21\u201353%, day 7 post-transduction) were impaired in K562 and MEG-01 cells. Moreover, <jats:italic toggle=\"yes\">JMJD1C<\/jats:italic> knockdown reduced the gemcitabine IC<jats:sub>50<\/jats:sub>-value for K562 cells (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.01) and MEG-01 cells (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.05) compared to scrambled shRNA control transduced cells.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Our results suggest that <jats:italic toggle=\"yes\">JMJD1C<\/jats:italic> is essential for proliferation, survival, and viability of K562 and MEG-01 cells. Further, <jats:italic toggle=\"yes\">JMJD1C<\/jats:italic> also potentially affects the cells gemcitabine\/carboplatin-sensitivity. Although further research is required, the findings show that <jats:italic toggle=\"yes\">JMJD1C<\/jats:italic> could have an influential role for gemcitabine\/carboplatin-sensitivity.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/fpc.0000000000000422","type":"journal-article","created":{"date-parts":[[2020,10,18]],"date-time":"2020-10-18T18:00:19Z","timestamp":1603044019000},"page":"60-67","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["JMJD1C knockdown affects myeloid cell lines proliferation, viability, and gemcitabine\/carboplatin-sensitivity"],"prefix":"10.1097","volume":"31","author":[{"given":"Vanessa","family":"Schimek","sequence":"first","affiliation":[{"name":"Clinical Pharmacology, Division of Drug Research, Department of Biomedical and Clinical Sciences, Link\u00f6ping University, Link\u00f6ping, Sweden"},{"name":"Surgical Research Laboratories, Department of Surgery and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niclas","family":"Bj\u00f6rn","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology, Division of Drug Research, Department of Biomedical and Clinical Sciences, Link\u00f6ping University, Link\u00f6ping, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Pell\u00e9","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology, Division of Drug Research, Department of Biomedical and Clinical Sciences, Link\u00f6ping University, Link\u00f6ping, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Svedberg","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology, Division of Drug Research, Department of Biomedical and Clinical Sciences, Link\u00f6ping University, Link\u00f6ping, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik","family":"Gr\u00e9en","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology, Division of Drug Research, Department of Biomedical and Clinical Sciences, Link\u00f6ping University, Link\u00f6ping, Sweden"},{"name":"Department of Forensic Genetics and Forensic Toxicology, National Board of Forensic Medicine, Link\u00f6ping, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,10,16]]},"reference":[{"key":"R1-20250808","first-page":"282","article-title":"Managing thrombocytopenia associated with cancer chemotherapy.","volume":"29","author":"Kuter","year":"2015","journal-title":"Oncology (Williston Park)"},{"key":"R2-20250808","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/tpj.2009.53","article-title":"Expression of gemcitabine- and cisplatin-related genes in non-small-cell lung cancer.","volume":"10","author":"Toffalorio","year":"2010","journal-title":"Pharmacogenomics J"},{"key":"R3-20250808","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1053\/j.seminhematol.2008.12.007","article-title":"Management of chemotherapy-induced thrombocytopenia: current status of thrombopoietic agents.","volume":"46","author":"Vadhan-Raj","year":"2009","journal-title":"Semin Hematol"},{"key":"R4-20250808","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/00002820-199904000-00011","article-title":"Gemcitabine: a pharmacologic and clinical overview.","volume":"22","author":"Barton-Burke","year":"1999","journal-title":"Cancer Nurs"},{"key":"R5-20250808","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/BF00257742","article-title":"Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II.","volume":"9","author":"Calvert","year":"1982","journal-title":"Cancer Chemother Pharmacol"},{"key":"R6-20250808","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/00001813-199707000-00005","article-title":"Safety profile of gemcitabine, a novel anticancer agent, in non-small cell lung cancer.","volume":"8","author":"Cortes-Funes","year":"1997","journal-title":"Anticancer Drugs"},{"key":"R7-20250808","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","article-title":"Cisplatin in cancer therapy: molecular mechanisms of action.","volume":"740","author":"Dasari","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"R8-20250808","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1200\/JCO.2008.20.9114","article-title":"Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer.","volume":"27","author":"Gr\u00f8nberg","year":"2009","journal-title":"J Clin Oncol"},{"key":"R9-20250808","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1159\/000330481","article-title":"Randomized phase II study of two schedules of carboplatin and gemcitabine for stage IIIB and IV advanced non-small cell lung cancer (JACCRO LC-01 study).","volume":"57","author":"Imamura","year":"2011","journal-title":"Chemotherapy"},{"key":"R10-20250808","doi-asserted-by":"crossref","first-page":"8380","DOI":"10.1200\/JCO.2005.01.2781","article-title":"Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group.","volume":"23","author":"Sederholm","year":"2005","journal-title":"J Clin Oncol"},{"key":"R11-20250808","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1158\/1078-0432.CCR-15-0964","article-title":"Using whole-exome sequencing to identify genetic markers for carboplatin and gemcitabine-induced toxicities.","volume":"22","author":"Gr\u00e9en","year":"2016","journal-title":"Clin Cancer Res"},{"key":"R12-20250808","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41397-019-0099-8","article-title":"Genes and variants in hematopoiesis-related pathways are associated with gemcitabine\/carboplatin-induced thrombocytopenia.","volume":"20","author":"Bj\u00f6rn","year":"2020","journal-title":"Pharmacogenomics J"},{"key":"R13-20250808","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.lungcan.2020.07.005","article-title":"Genetic association of gemcitabine\/carboplatin-induced leukopenia and neutropenia in non-small cell lung cancer patients using whole-exome sequencing.","volume":"147","author":"Svedberg","year":"2020","journal-title":"Lung Cancer"},{"key":"R14-20250808","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41540-020-00146-6","article-title":"Whole-genome sequencing and gene network modules predict gemcitabine\/carboplatin-induced myelosuppression in non-small cell lung cancer patients.","volume":"6","author":"Bj\u00f6rn","year":"2020","journal-title":"NPJ Syst Biol Appl"},{"key":"R15-20250808","doi-asserted-by":"crossref","first-page":"549","DOI":"10.3390\/genes11050549","article-title":"Single-cell RNA sequencing of hematopoietic stem and progenitor cells treated with gemcitabine and carboplatin.","volume":"11","author":"Bjorn","year":"2020","journal-title":"Genes (Basel)"},{"key":"R16-20250808","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.stem.2010.07.016","article-title":"Combinatorial transcriptional control in blood stem\/progenitor cells: genome-wide analysis of ten major transcriptional regulators.","volume":"7","author":"Wilson","year":"2010","journal-title":"Cell Stem Cell"},{"key":"R17-20250808","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1101\/gad.267278.115","article-title":"JMJD1C is required for the survival of acute myeloid leukemia by functioning as a coactivator for key transcription factors.","volume":"29","author":"Chen","year":"2015","journal-title":"Genes Dev"},{"key":"R18-20250808","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/nature10659","article-title":"New gene functions in megakaryopoiesis and platelet formation.","volume":"480","author":"Gieger","year":"2011","journal-title":"Nature"},{"key":"R19-20250808","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s11239-015-1290-7","article-title":"Replication and hematological characterization of human platelet reactivity genetic associations in men from the Caerphilly Prospective Study (CaPS).","volume":"41","author":"Eicher","year":"2016","journal-title":"J Thromb Thrombolysis"},{"key":"R20-20250808","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00439-013-1355-7","article-title":"A genome- and phenome-wide association study to identify genetic variants influencing platelet count and volume and their pleiotropic effects.","volume":"133","author":"Shameer","year":"2014","journal-title":"Hum Genet"},{"key":"R21-20250808","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1038\/ng.467","article-title":"A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium.","volume":"41","author":"Soranzo","year":"2009","journal-title":"Nat Genet"},{"key":"R22-20250808","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0301-472X(00)00686-X","article-title":"A role of jumonji gene in proliferation but not differentiation of megakaryocyte lineage cells.","volume":"29","author":"Kitajima","year":"2001","journal-title":"Exp Hematol"},{"key":"R23-20250808","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/s41375-018-0354-z","article-title":"JMJD1C-mediated metabolic dysregulation contributes to HOXA9-dependent leukemogenesis.","volume":"33","author":"Lynch","year":"2019","journal-title":"Leukemia"},{"key":"R24-20250808","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1182\/bloodadvances.2018026054","article-title":"Critical role of Jumonji domain of JMJD1C in MLL-rearranged leukemia.","volume":"3","author":"Izaguirre-Carbonell","year":"2019","journal-title":"Blood Adv"},{"key":"R25-20250808","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1182\/blood-2013-08-522094","article-title":"shRNA screening identifies JMJD1C as being required for leukemia maintenance.","volume":"123","author":"Sroczynska","year":"2014","journal-title":"Blood"},{"key":"R26-20250808","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/blood-2016-05-714493","article-title":"The EMT regulator ZEB2 is a novel dependency of human and murine acute myeloid leukemia.","volume":"129","author":"Li","year":"2017","journal-title":"Blood"},{"key":"R27-20250808","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/ijc.32552","article-title":"Small molecular modulators of JMJD1C preferentially inhibit growth of leukemia cells.","volume":"146","author":"Xu","year":"2020","journal-title":"Int J Cancer"},{"key":"R28-20250808","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1182\/blood.V45.3.321.321","article-title":"Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome.","volume":"45","author":"Lozzio","year":"1975","journal-title":"Blood"},{"key":"R29-20250808","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/0145-2126(79)90033-X","article-title":"Properties and usefulness of the original K-562 human myelogenous leukemia cell line.","volume":"3","author":"Lozzio","year":"1979","journal-title":"Leuk Res"},{"key":"R30-20250808","doi-asserted-by":"crossref","first-page":"546","DOI":"10.3181\/00379727-166-41106","article-title":"A multipotential leukemia cell line (K-562) of human origin.","volume":"166","author":"Lozzio","year":"1981","journal-title":"Proc Soc Exp Biol Med"},{"key":"R31-20250808","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1182\/blood.V66.6.1384.1384","article-title":"Establishment of a novel human megakaryoblastic leukemia cell line, MEG-01, with positive Philadelphia chromosome.","volume":"66","author":"Ogura","year":"1985","journal-title":"Blood"},{"key":"R32-20250808","first-page":"115","article-title":"Histone demethylase JMJD1C regulates esophageal cancer proliferation Via YAP1 signaling.","volume":"7","author":"Cai","year":"2017","journal-title":"Am J Cancer Res"},{"key":"R33-20250808","doi-asserted-by":"crossref","first-page":"26.2.1","DOI":"10.1002\/0471142727.mb2602s111","article-title":"Gene silencing by RNAi in mammalian cells.","volume":"111","author":"Ponthan","year":"2015","journal-title":"Curr Protoc Mol Biol"},{"key":"R34-20250808","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13104-015-1000-8","article-title":"Limitations of the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay when compared to three commonly used cell enumeration assays.","volume":"8","author":"van Tonder","year":"2015","journal-title":"BMC Res Notes"},{"key":"R35-20250808","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.3390\/ijms18081679","article-title":"Do multiwell plate high throughput assays measure loss of cell viability following exposure to genotoxic agents?","volume":"18","author":"Mirzayans","year":"2017","journal-title":"Int J Mol Sci"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0000000000000422","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T13:01:47Z","timestamp":1754658107000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0000000000000422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,16]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0000000000000422","relation":{},"ISSN":["1744-6872"],"issn-type":[{"type":"print","value":"1744-6872"}],"subject":[],"published":{"date-parts":[[2020,10,16]]}}}